Inhibition of glioblastoma cell proliferation, migration and invasion by the proteasome antagonist carfilzomib. (Q38776733)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27098175 AND SRC:MED&resulttype=core&format=json

2 April 2020

title

Inhibition of glioblastoma cell proliferation, migration and invasion by the proteasome antagonist carfilzomib (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27098175 AND SRC:MED&resulttype=core&format=json

2 April 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27098175 AND SRC:MED&resulttype=core&format=json

2 April 2020

Andrew Morokoff

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27098175 AND SRC:MED&resulttype=core&format=json

2 April 2020

Andrew H. Kaye

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27098175 AND SRC:MED&resulttype=core&format=json

2 April 2020

Rodney B Luwor

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27098175 AND SRC:MED&resulttype=core&format=json

2 April 2020

author name string

Zammam Areeb

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27098175 AND SRC:MED&resulttype=core&format=json

2 April 2020

Thomas M B Ware

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27098175 AND SRC:MED&resulttype=core&format=json

2 April 2020

Nicole C Harris

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27098175 AND SRC:MED&resulttype=core&format=json

2 April 2020

Lipi Shukla

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27098175 AND SRC:MED&resulttype=core&format=json

2 April 2020

Ramin Shayan

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27098175 AND SRC:MED&resulttype=core&format=json

2 April 2020

Lucia Paradiso

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27098175 AND SRC:MED&resulttype=core&format=json

2 April 2020

Bo Li

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27098175 AND SRC:MED&resulttype=core&format=json

2 April 2020

publication date

20 April 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27098175 AND SRC:MED&resulttype=core&format=json

2 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27098175 AND SRC:MED&resulttype=core&format=json

2 April 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27098175 AND SRC:MED&resulttype=core&format=json

2 April 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27098175 AND SRC:MED&resulttype=core&format=json

2 April 2020

page(s)

53

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27098175 AND SRC:MED&resulttype=core&format=json

Glioblastoma multiforme: a review of where we have been and where we are going

2 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Management of glioblastoma in Victoria, Australia (2006-2008).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Orthotopic glioblastoma stem-like cell xenograft model in mice to evaluate intra-arterial delivery of bevacizumab: from bedside to bench

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

The role of Stat3 in glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Effects of EGF, bFGF, NGF and PDGF(bb) on cell proliferative, migratory and invasive capacities of human brain-tumour biopsies in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

PDGF and PDGF receptors in glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Sunitinib administered prior to radiotherapy in patients with non-resectable glioblastoma: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

PTEN signaling in brain: neuropathology and tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Heterogeneous phenotype of human glioblastoma: in vitro study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Mechanism of chemoresistance against tyrosine kinase inhibitors in malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Bortezomib in multiple myeloma: systematic review and clinical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

The ubiquitin proteasome system and efficacy of proteasome inhibitors in diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

The shaping of invasive glioma phenotype by the ubiquitin-proteasome system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Proteasome inhibitors in cancer therapy: lessons from the first decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Bortezomib for the treatment of multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Efficacy of low dose temozolomide in combination with bortezomib in U87 glioma cells: a flow cytometric analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Proteasome inhibitors in multiple myeloma: 10 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Therapeutic strategies for inhibiting invasion in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Recent medical management of glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Glioblastoma and other malignant gliomas: a clinical review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Recent developments in the use of chemotherapy in brain tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Characterization of caspase-dependent and caspase-independent deaths in glioblastoma cells treated with inhibitors of the ubiquitin-proteasome system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKCε-dependent downregulation of AKT and XIAP expressions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Inhibition of autophagy enhances apoptosis induced by proteasome inhibitor bortezomib in human glioblastoma U87 and U251 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

The EGFRvIII variant in glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Epidermal growth factor receptor vIII expression in U87 glioblastoma cells alters their proteasome composition, function, and response to irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

New functions for the matrix metalloproteinases in cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Induction of Cell Migration by Matrix Metalloprotease-2 Cleavage of Laminin-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

Characterization of matrix metalloproteinase-2 and -9, ADAM-10 and N-cadherin expression in human glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12032-016-0767-3

21 January 2018

1 reference

12 December 2020

Activity of bortezomib in glioblastoma.

1 reference

12 December 2020

Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib

1 reference

12 December 2020

Cell scattering and migration induced by autocrine transforming growth factor alpha in human glioma cells in vitro

1 reference

12 December 2020

Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.

1 reference

12 December 2020

Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study.

1 reference

12 December 2020

Loss of PTEN facilitates HIF-1-mediated gene expression

1 reference

12 December 2020

Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma

1 reference

12 December 2020

Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma

1 reference

12 December 2020

A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis

1 reference

12 December 2020

10.1007/S12032-016-0767-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27098175 AND SRC:MED&resulttype=core&format=json

Dimensions Publication ID

2 April 2020

1042628761

0 references

Fatcat ID

release_fhur3pucjzcizd6hpz6okgq6p4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/fhur3pucjzcizd6hpz6okgq6p4

24 November 2022

mapped directly with Wikidata item

1 reference